We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Clinical trial results suggest an increased risk of atrial fibrillation for zoledronic acid (Aclasta▼), pamidronic acid, and possibly for alendronic acid, although the balance-risk remains favourable for bisphosphonates.
A pooled analysis has shown an increased rate of new primary malignancies in patients given Xgeva (1-year cumulative incidence 1.1%) compared with those given zoledronic acid (0.6%), when used in the indication of the preven…
Projects granted during 2014 that have a primary purpose of basic research into the musculoskeletal system.
Before prescribing hormone-replacement therapy, healthcare professionals should consider carefully the potential benefits and risks for every woman
Now only authorised for use in patients with symptomatic bone metastases and no known visceral metastases who have had 2 previous systemic treatments for metastatic castration-resistant prostate cancer or who cannot receive …
To help public health, health professionals, paid social care staff and family members to prevent falls in people with learning disabilities.
Monitor patients for signs and symptoms of hypercalcaemia after discontinuation of denosumab treatment for giant cell tumour of bone. Cases of rebound hypercalcemia have been reported up to 9 months after cessation of treatm…
Risk of early psychiatric side-effects is one of several important safety issues for healthcare professionals to discuss with patients and carers, who should seek urgent medical advice in the event of any worrying symptoms.
Information to help health professionals prevent ill health and promote wellbeing as part of their everyday practice.
Insufficient evidence to confirm a link between oral bisphosphonate use and an increased risk of oesophageal cancer.
Increased risk of stroke in older women should be taken into account in prescribing decisions.
Employment Tribunal decision.
This resource for health professionals and local authorities makes the case for action to support healthy productive later life.
How MHRA monitors the impact of regulatory action taken.
Update of data on musculoskeletal conditions and services for local populations in England.
This report summarises the work of the UK National Screening Committee (UK NSC) to review screening recommendations from 1 April 2019 to 31 March 2020.
Upper Tribunal Administrative Appeals Chamber decision by Judge Clough on 27 August 2021.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).